



Clinical trial results:

A randomised, multinational, active-controlled,(open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency

Summary

EudraCT number	2015-000531-32
Trial protocol	AT SE SI DE BE
Global end of trial date	26 September 2024

Results information

Result version number	v1 (current)
This version publication date	11 April 2025
First version publication date	11 April 2025

Trial information

Trial identification

Sponsor protocol code	NN8640-4172
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02616562
WHO universal trial number (UTN)	U1111-1166-7062

Notes:

Sponsors

Sponsor organisation name	Novo Nordisk A/S
Sponsor organisation address	Novo Alle, Bagsvaerd, Denmark, 2880
Public contact	Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com
Scientific contact	Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 November 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 September 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Cohort I: To evaluate the efficacy of multiple dose regimens of once-weekly somapacitan after 26 weeks of treatment in Growth Hormone (GH) treatment naive pre-pubertal children with Growth hormone deficiency (GHD) compared to once-daily human growth hormone (hGH) administration (Norditropin Flexpro)

Cohort II and III: To evaluate the safety of once-weekly somapacitan during up to 208 weeks of treatment in children with GHD.

Protection of trial subjects:

The trial was conducted in accordance with the Declaration of Helsinki (Oct 2013) and International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) Good Clinical Practice, including archiving of essential documents, (May 1996) and 21 Code of Federal Regulations (CFR) 312.120.

Background therapy:

Not applicable

Evidence for comparator: -

Actual start date of recruitment	23 March 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 2
Country: Number of subjects enrolled	Brazil: 1
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	India: 14
Country: Number of subjects enrolled	Israel: 8
Country: Number of subjects enrolled	Japan: 17
Country: Number of subjects enrolled	Slovenia: 3
Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	Türkiye: 2
Country: Number of subjects enrolled	Ukraine: 7
Country: Number of subjects enrolled	United States: 15
Worldwide total number of subjects	76
EEA total number of subjects	12

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	67
Adolescents (12-17 years)	9
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The trial was conducted at 30 sites in 11 countries.

Pre-assignment

Screening details:

Subjects (cohort I) given somapacitan/Norditropin in main & extension period & safety extension period. After which (from week 156), all subjects were given somapacitan for long-term safety extension period. Subjects in cohorts II and III were given somapacitan from enrolment (week 156).

Period 1

Period 1 title	Main and Extension period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

The main & extension trial period was double-blinded with regard to different dose levels of somapacitan but open-labelled with regard to daily Norditropin as active control arm.

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort I Norditropin/somapacitan

Arm description:

Subjects received Norditropin 0.034 miligram per kilogram (mg/kg) subcutaneously once weekly during (26 week) main trial period and (26 week) extension trial period.

Arm type	Experimental
Investigational medicinal product name	Norditropin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Norditropin 0.034mg/kg was given subcutaneously daily from week 0 to week 52

Arm title	Cohort I somapacitan pooled
------------------	-----------------------------

Arm description:

Subjects were randomized (1:1:1) to receive somapacitan treatment (0.04/0.08/0.16 mg/kg/week) subcutaneously once-weekly during the (26 week) main trial period and (26 week) extension trial period.

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.04/0.08/0.16mg was given subcutaneously once weekly from week 0 to week 52.

Number of subjects in period 1 ^[1]	Cohort I Norditropin/somapacitan	Cohort I somapacitan pooled
Started	14	45
Completed	14	44
Not completed	0	1
Withdrawal by parent/guardian	-	1

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The worldwide number of subjects enrolled in the trial are 76. 17 participants entered the trial in the long-term safety extension period and hence are not a part of the baseline period

Period 2

Period 2 title	Safety extension period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

After week 52, the trial was open-labelled with one dose level of somapacitan and Norditropin.

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort I Norditropin/somapacitan

Arm description:

Subjects received Norditropin 0.034 milligram per kilogram (mg/kg) subcutaneously once weekly during (104 week) safety extension period.

Arm type	Experimental
Investigational medicinal product name	Norditropin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Norditropin 0.034mg/kg was given subcutaneously daily from week 52 to week 156

Arm title	Cohort I somapacitan pooled
------------------	-----------------------------

Arm description:

Subjects initially randomized to double-blinded somapacitan treatment 0.04/0.08/0.16mg/kg/week during main and extension period received open-labelled somapacitan treatment 0.16 mg/kg/week subcutaneously once-weekly during 104 week safety extension period.

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16mg/kg was given subcutaneously once weekly from week 52 to week 156.

Number of subjects in period 2	Cohort I Norditropin/somapacitan	Cohort I somapacitan pooled
Started	14	44
Completed	12	41
Not completed	2	3
Withdrawal by parent/guardian	-	1
treatment discontinued before visit 5	1	1
Lost to follow-up	-	1
Protocol deviation	1	-

Period 3

Period 3 title	Long term safety extension period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

After week 156, the trial was open-labelled with one dose level of somapacitan.

Arms

Are arms mutually exclusive?	No
Arm title	Cohort I Norditropin/somapacitan

Arm description:

Subjects who received Norditropin until week 156 were given somapacitan 0.16 mg/kg subcutaneously once weekly for the 208-week long terms safety extension period (up till week 364)

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg was given subcutaneously once weekly from week 156 to week 364

Arm title	Cohort I somapacitan pooled
------------------	-----------------------------

Arm description:

Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly for the 208-week long terms safety extension period (up till week 364)

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg was given subcutaneously once weekly from week 156 to week 364

Arm title	Cohort II somapacitan previously treated
------------------	--

Arm description:

Subject who was previously treated with GH (Growth hormone) prior to enrollment in the trial at week 156, received somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg given subcutaneously once weekly from week 156 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Arm title	Cohort III somapacitan treatment naive
------------------	--

Arm description:

Subjects who were naive to treatment with GH prior to enrollment in the trial at week 156, received open-labelled somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg given subcutaneously once weekly from week 156 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Arm title	Cohort III somapacitan previously treated
------------------	---

Arm description:

Subjects who were previously treated with GH prior to enrollment in the trial at week 156, received open-labelled somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg given subcutaneously once weekly from week 156 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Number of subjects in period 3	Cohort I Norditropin/somapacitan	Cohort I somapacitan pooled	Cohort II somapacitan previously treated
Started	12	41	1
Completed	10	33	1
Not completed	2	8	0
Withdrawal by parent/guardian	-	4	-
Consent withdrawn by subject	1	-	-

Subject was discontinued from trial	-	1	-
Lost to follow up	-	-	-
Adult height reached	-	-	-
Growth velocity in 9 months is 1 cm (1.3 CM/Y)	1	-	-
adverse event	-	1	-
Principal Investigator's decision	-	1	-
Protocol deviation	-	1	-

Number of subjects in period 3	Cohort III somapacitan treatment naive	Cohort III somapacitan previously treated
Started	4	12
Completed	2	9
Not completed	2	3
Withdrawal by parent/guardian	-	1
Consent withdrawn by subject	1	1
Subject was discontinued from trial	-	-
Lost to follow up	1	-
Adult height reached	-	1
Growth velocity in 9 months is 1 cm (1.3 CM/Y)	-	-
adverse event	-	-
Principal Investigator's decision	-	-
Protocol deviation	-	-

Period 4

Period 4 title	Extension after week 364
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

After week 156, the trial was open-labelled with one dose level of somapacitan.

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort I Norditropin/somapacitan

Arm description:

Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection, Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg given subcutaneously once weekly from week 364 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Arm title	Cohort I somapacitan pooled
------------------	-----------------------------

Arm description:

Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Arm type	Experimental
Investigational medicinal product name	somapacitan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

somapacitan 0.16 mg/kg given subcutaneously once weekly from week 364 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Number of subjects in period 4	Cohort I Norditropin/somapacitan	Cohort I somapacitan pooled
Started	10	33
Completed	5	17
Not completed	5	16
Somapacitan available in their country	5	16

Baseline characteristics

Reporting groups

Reporting group title	Main and Extension period
Reporting group description: In Cohort I Norditropin/somapacitan arm subjects received Norditropin 0.034 miligram per kilogram (mg/kg) subcutaneously once weekly during (26 week) main trial period and (26 week) extension trial period. And in Cohort I somapacitan pooled arm subjects were randomized (1:1:1) to receive somapacitan treatment (0.04/0.08/0.16 mg/kg) subcutaneously once-weekly during the (26 week) main trial period and (26 week) extension trial period.	

Reporting group values	Main and Extension period	Total	
Number of subjects	59	59	
Age Categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	59	59	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age Continuous Units: years			
arithmetic mean	5.84		
standard deviation	± 1.94	-	
Gender Categorical Units: Subjects			
Female	23	23	
Male	36	36	

Subject analysis sets

Subject analysis set title	Norditropin 0.034 mg/kg/day
Subject analysis set type	Full analysis
Subject analysis set description: Subjects received Norditropin 0.034 mg/kg subcutaneously daily during 26 weeks main trial period.	
Subject analysis set title	somapacitan 0.04mg/kg/week
Subject analysis set type	Full analysis
Subject analysis set description: Subjects received somapacitan 0.04 mg/kg subcutaneously once weekly during 26 weeks main trial period.	
Subject analysis set title	somapacitan 0.08mg/kg/week
Subject analysis set type	Full analysis
Subject analysis set description: Subjects received somapacitan 0.08 mg/kg subcutaneously once weekly during 26 weeks main trial period.	

Subject analysis set title	somapacitan 0.16mg/kg/week
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly during 26 weeks main trial period.	
Subject analysis set title	Norditropin 0.034mg/kg/day 0-156 week Cohort I
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects were randomized to receive Norditropin 0.034mg daily in main trial, extension trial period and safety extension trial period.	
Subject analysis set title	Norditropin /somapacitan (0.16mg/kg/week) week 156-364
Subject analysis set type	Full analysis
Subject analysis set description:	
After completing the safety extension trial period (week 156), subjects who received Norditropin were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week (up till week 364) long-term safety extension period.	
Subject analysis set title	Cohort II & Cohort III
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received somapacitan 0.16mg/kg/weekly subcutaneously from week 156 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.	
Subject analysis set title	Cohort I Norditropin/somapacitan
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects received Norditropin 0.034 mg/kg subcutaneously once weekly in main trial period (26 weeks), extension trial period (26 weeks) and 104 week safety extension trial period. In long terms safety extension period all subjects who received Norditropin 0.034 mg/kg were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week long term safety extension period (up till week 364).	
Subject analysis set title	Cohort I somapacitan pooled
Subject analysis set type	Full analysis
Subject analysis set description:	
Subjects were randomized (1:1:1) to receive somapacitan treatment (0.04/0.08/0.16 mg/kg) subcutaneously once-weekly during the 26-week main trial period and the 26-week extension trial period. After completing the main and extension trial periods (week 52), all subjects initially randomized to double-blinded somapacitan received open-labelled somapacitan 0.16 mg/kg/week treatment for the 104-week safety extension trial period. After completing the safety extension trial period (week 156), all subjects in cohort I were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week (up till week 364) long-term safety extension period.	

Reporting group values	Norditropin 0.034 mg/kg/day	somapacitan 0.04mg/kg/week	somapaciatn 0.08mg/kg/week
Number of subjects	14	14	15
Age Categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			

Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Gender Categorical Units: Subjects			
Female Male			

Reporting group values	somapacitan 0.16mg/kg/week	Norditropin 0.034mg/kg/day 0- 156 week Cohort I	Norditropin /somapacitan (0.16mg/kg/week) week 156-364
Number of subjects	14	14	11
Age Categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Gender Categorical Units: Subjects			
Female Male			

Reporting group values	Cohort II & Cohort III	Cohort I Norditropin/somapacitan	Cohort I somapacitan pooled
Number of subjects	17	14	45
Age Categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over	8 9		

Age Continuous Units: years arithmetic mean standard deviation	\pm	\pm	\pm
Gender Categorical Units: Subjects			
Female	2		
Male	15		

End points

End points reporting groups

Reporting group title	Cohort I Norditropin/somapacitan
Reporting group description: Subjects received Norditropin 0.034 miligram per kilogram (mg/kg) subcutaneously once weekly during (26 week) main trial period and (26 week) extension trial period.	
Reporting group title	Cohort I somapacitan pooled
Reporting group description: Subjects were randomized (1:1:1) to receive somapacitan treatment (0.04/0.08/0.16 mg/kg/week) subcutaneously once-weekly during the (26 week) main trial period and (26 week) extension trial period.	
Reporting group title	Cohort I Norditropin/somapacitan
Reporting group description: Subjects received Norditropin 0.034 miligram per kilogram (mg/kg) subcutaneously once weekly during (104 week) safety extension period.	
Reporting group title	Cohort I somapacitan pooled
Reporting group description: Subjects initially randomized to double-blinded somapacitan treatment 0.04/0.08/0.16mg/kg/week during main and extension period received open-labelled somapacitan treatment 0.16 mg/kg/week subcutaneously once-weekly during 104 week safety extension period.	
Reporting group title	Cohort I Norditropin/somapacitan
Reporting group description: Subjects who received Norditropin until week 156 were given somapacitan 0.16 mg/kg subcutaneously once weekly for the 208-week long terms safety extension period (up till week 364)	
Reporting group title	Cohort I somapacitan pooled
Reporting group description: Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly for the 208-week long terms safety extension period (up till week 364)	
Reporting group title	Cohort II somapacitan previously treated
Reporting group description: Subject who was previously treated with GH (Growth hormone) prior to enrollment in the trial at week 156, received somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.	
Reporting group title	Cohort III somapacitan treatment naive
Reporting group description: Subjects who were naive to treatment with GH prior to enrollment in the trial at week 156, received open-labelled somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.	
Reporting group title	Cohort III somapacitan previously treated
Reporting group description: Subjects who were previously treated with GH prior to enrollment in the trial at week 156, received open-labelled somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.	
Reporting group title	Cohort I Norditropin/somapacitan
Reporting group description: Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.	
Reporting group title	Cohort I somapacitan pooled
Reporting group description: Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.	
Subject analysis set title	Norditropin 0.034 mg/kg/day
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects received Norditropin 0.034 mg/kg subcutaneously daily during 26 weeks main trial period.

Subject analysis set title	somapacitan 0.04mg/kg/week
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects received somapacitan 0.04 mg/kg subcutaneously once weekly during 26 weeks main trial period.

Subject analysis set title	somapacitan 0.08mg/kg/week
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects received somapacitan 0.08 mg/kg subcutaneously once weekly during 26 weeks main trial period.

Subject analysis set title	somapacitan 0.16mg/kg/week
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly during 26 weeks main trial period.

Subject analysis set title	Norditropin 0.034mg/kg/day 0-156 week Cohort I
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects were randomized to receive Norditropin 0.034mg daily in main trial, extension trial period and safety extension trial period.

Subject analysis set title	Norditropin /somapacitan (0.16mg/kg/week) week 156-364
Subject analysis set type	Full analysis

Subject analysis set description:

After completing the safety extension trial period (week 156), subjects who received Norditropin were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week (up till week 364) long-term safety extension period.

Subject analysis set title	Cohort II & Cohort III
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects received somapacitan 0.16mg/kg/weekly subcutaneously from week 156 until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Subject analysis set title	Cohort I Norditropin/somapacitan
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects received Norditropin 0.034 mg/kg subcutaneously once weekly in main trial period (26 weeks), extension trial period (26 weeks) and 104 week safety extension trial period. In long terms safety extension period all subjects who received Norditropin 0.034 mg/kg were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week long term safety extension period (up till week 364).

Subject analysis set title	Cohort I somapacitan pooled
Subject analysis set type	Full analysis

Subject analysis set description:

Subjects were randomized (1:1:1) to receive somapacitan treatment (0.04/0.08/0.16 mg/kg) subcutaneously once-weekly during the 26-week main trial period and the 26-week extension trial period. After completing the main and extension trial periods (week 52), all subjects initially randomized to double-blinded somapacitan received open-labelled somapacitan 0.16 mg/kg/week treatment for the 104-week safety extension trial period. After completing the safety extension trial period (week 156), all subjects in cohort I were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week (up till week 364) long-term safety extension period.

Primary: Cohort I: Height velocity (HV) (cm/year) during first 26 week of treatment, measured as standing height with stadiometer

End point title	Cohort I: Height velocity (HV) (cm/year) during first 26 week of treatment, measured as standing height with stadiometer
-----------------	--

End point description:

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and the week

26 as: HV = (height at 26 weeks visit- height at baseline) / (time from baseline to 26 weeks visit in years). Full analysis set (FAS) was used to analyse this endpoint. FAS is defined as all randomized subjects that received at least one dose of randomized treatment.

End point type	Primary
End point timeframe:	
At baseline and after 26 weeks	

End point values	Norditropin 0.034 mg/kg/day	somapacitan 0.04mg/kg/we ek	somapaciatn 0.08mg/kg/we ek	somapcitan 0.16mg/kg/we ek
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	14	15	14
Units: Centimeter per year (Cm/year)				
arithmetic mean (standard deviation)	11.35 (± 3.27)	7.96 (± 2.04)	10.92 (± 1.90)	12.88 (± 3.46)

Statistical analyses

Statistical analysis title	Norditropin vs Somapacitan
-----------------------------------	----------------------------

Statistical analysis description:

The primary analysis tested the estimated treatment difference in HV after 26 weeks of treatment between once-weekly Somapacitan 0.04 mg/kg and daily dosing of Norditropin (0.034 mg/kg). It was analysed using a mixed model for repeated measurements, with treatment, age group, sex, region and sex by age group interaction as factors and height at baseline as a covariate, all nested within week as a factor.

Comparison groups	Norditropin 0.034 mg/kg/day v somapacitan 0.04mg/kg/week
Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Estimated Treatment difference
Point estimate	-3.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.57
upper limit	-1.76

Statistical analysis title	Norditropin vs Somapacitan
-----------------------------------	----------------------------

Statistical analysis description:

The primary analysis tested the estimated treatment difference in HV after 26 weeks of treatment between once-weekly Somapacitan 0.16 mg/kg and daily dosing of Norditropin (0.034 mg/kg). It was analysed using a mixed model for repeated measurements, with treatment, age group, sex, region and sex by age group interaction as factors and height at baseline as a covariate, all nested within week as a factor.

Comparison groups	Norditropin 0.034 mg/kg/day v somapcitan 0.16mg/kg/week
-------------------	---

Number of subjects included in analysis	28
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Estimated treatment difference
Point estimate	1.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	3.56

Statistical analysis title	Norditropin vs Somapacitan
-----------------------------------	----------------------------

Statistical analysis description:

The primary analysis tested the estimated treatment difference in HV after 26 weeks of treatment between once-weekly Somapacitan 0.08 mg/kg and daily dosing of Norditropin (0.034 mg/kg). It was analysed using a mixed model for repeated measurements, with treatment, age group, sex, region and sex by age group interaction as factors and height at baseline as a covariate, all nested within week as a factor.

Comparison groups	Norditropin 0.034 mg/kg/day v somapacitan 0.08mg/kg/week
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Estimated treatment difference
Point estimate	-0.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.41
upper limit	1.32

Primary: Cohort II and III: Incidence of adverse events, including injection site reactions in children with GHD.

End point title	Cohort II and III: Incidence of adverse events, including injection site reactions in children with GHD. ^[1]
-----------------	---

End point description:

The primary endpoint was analysed by cohort using descriptive statistics. All participants of Cohort II and Cohort III were analysed for this endpoint. All participants defined as: all adverse events with an onset after the first administration of trial product and up until 14 days after last trial drug administration for withdrawn participants, and with an onset after the first administration of trial product and up until visit 32 (week 208) or 14 days after last trial drug administration, whichever ever comes first, for all participants are included in the analysis.

End point type	Primary
----------------	---------

End point timeframe:

During up to 208 weeks of treatment

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary endpoint investigated safety and was analysed using descriptive statistics, and thus no statistical analysis was performed.

End point values	Cohort II somapacitan previously treated	Cohort III somapacitan treatment naive	Cohort III somapacitan previously treated	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	1	4	12	
Units: Events	42	12	55	

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort I: Change in Height standard deviation score (HSDS)

End point title	Cohort I: Change in Height standard deviation score (HSDS)
End point description:	
Change in height standard deviation score is presented from baseline (week 0) to end of the main trial period week 26. The formula to calculate HSDS is: $HSDS = ((Height / M)^{L-1} / (L \cdot S))$. L: The sex and age-specific power in the Box-Cox transformation, M: The sex and age-specific median, S: The sex and age-specific generalized coefficient of variation. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. FAS was used to analyse this endpoint. (FAS) is defined as all randomised subjects that received at least one dose of randomised treatment.	
End point type	Secondary
End point timeframe:	
From baseline to end of main trial period (week 26)	

End point values	Norditropin 0.034 mg/kg/day	somapacitan 0.04mg/kg/we ek	somapaciatn 0.08mg/kg/we ek	somapcitan 0.16mg/kg/we ek
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	14	15	14
Units: Score on scale				
arithmetic mean (standard deviation)	0.66 (± 0.37)	0.31 (± 0.29)	0.63 (± 0.29)	0.88 (± 0.52)

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort I: Change in Height velocity standard deviation score (HVSDS)

End point title	Cohort I: Change in Height velocity standard deviation score (HVSDS)
End point description:	
Change in height velocity standard deviation score is presented from baseline (week 0) to end of main trial period week 26. HVSDS was calculated using the formula: $HVSDS = (height\ velocity - mean) / standard\ deviation\ (SD)$, where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height	

velocity for a child with the same age and gender. FAS was used to analyse this endpoint. (FAS) is defined as all randomised subjects that received at least one dose of randomised treatment.

End point type	Secondary
End point timeframe:	
From baseline to end of main trial period (week 26)	

End point values	Norditropin 0.034 mg/kg/day	somapacitan 0.04mg/kg/we ek	somapaciatn 0.08mg/kg/we ek	somapcitan 0.16mg/kg/we ek
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	14	15	14
Units: Score on scale				
arithmetic mean (standard deviation)	9.02 (± 5.03)	4.93 (± 3.25)	7.27 (± 3.76)	10.01 (± 4.67)

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort I: Incidence of adverse events, including injection site reactions

End point title	Cohort I: Incidence of adverse events, including injection site reactions
-----------------	---

End point description:

Adverse events with an onset after the first administration of trial product and up until 14 days after last trial drug administration for withdrawn participants, and with an onset after the first administration of trial product and up until visit 32 (week 364) or 14 days after last trial drug administration, which ever comes first, for all other participants, are analysed. Safety analysis set (SAS) was used to analyse this endpoint. SAS is defined as all randomized subjects that received at least one dose of randomized treatment.

End point type	Secondary
End point timeframe:	
Up to 364 weeks of treatment	

End point values	Norditropin 0.034mg/kg/day 0-156 week Cohort I	Norditropin /somapacitan (0.16mg/kg/we ek) week 156- 364	Cohort I somapacitan pooled	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	14	11	45	
Units: events	95	46	582	

Statistical analyses

No statistical analyses for this end point

Secondary: Cohort I: Occurrence of anti-NNC0195-0092 and anti-hGH antibodies

End point title	Cohort I: Occurrence of anti-NNC0195-0092 and anti-hGH antibodies
-----------------	---

End point description:

Subjects who developed anti-NNC0195-0092 and anti-hGH antibodies are reported in this endpoint. Safety analysis set (SAS) was used to analyse this endpoint. SAS is defined as all randomized subjects that received at least one dose of randomized treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 364 weeks of treatment

End point values	Cohort I Norditropin/so mapacitan	Cohort I somapacitan pooled		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	14	45		
Units: Participants				
Anti-NNC0195-0092 antibody	0	12		
Anti-hGH antibody	1	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Week 0 to week 442

Adverse event reporting additional description:

Cohort I: SAS

All presented AEs are TEAEs (treatment emergent adverse events).

Cohort II & III: All participants

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27
--------------------	----

Reporting groups

Reporting group title	Cohort I Norditropin (0.034mg/kg/day) week 0-156
-----------------------	--

Reporting group description:

Subjects received Norditropin 0.034 mg/kg subcutaneously daily in main trial, extension trial period and safety extension trial period.

Reporting group title	Cohort I Norditropin (0.034mg/somapacitan 0.16mg) week 156-364
-----------------------	--

Reporting group description:

After completing the safety extension trial period (week 156), subjects who received Norditropin were allocated to open-labelled Somapacitan 0.16 mg/kg subcutaneously once weekly for the 208-week (up till week 364) long-term safety extension period.

Reporting group title	Cohort I somapacitan (0.04/0.08/0.16mg/kg/week) pooled
-----------------------	--

Reporting group description:

Subjects were randomized (1:1:1) to receive Somapacitan treatment (0.04/0.08/0.16 mg/kg) subcutaneously once-weekly during the 26-week main trial period and the 26-week extension trial period. After completing the main and extension trial periods (week 52), all subjects initially randomized to double-blinded Somapacitan received open-labelled Somapacitan 0.16 mg/kg/week treatment for the 104-week safety extension trial period. After completing the safety extension trial period (week 156), all subjects in cohort I were allocated to open-labelled somapacitan 0.16 mg/kg/week for the 208-week (up till week 364) long-term safety extension period. In extension after week 364 period subjects received somapacitan 0.16 mg/kg subcutaneously once weekly until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Reporting group title	Cohort II somapacitan(0.16mg/kg/week) previously treated
-----------------------	--

Reporting group description:

Subject who was previously treated with GH (Growth hormone) prior to enrollment in the trial at week 156, received somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.

Reporting group title	Cohort III somapacitan(0.16mg/kg/week) treatment naive
-----------------------	--

Reporting group description:

Subjects who were naive to treatment with GH prior to enrollment in the trial at week 156, received open-labelled somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.

Reporting group title	Cohort III somapacitan(0.16mg/kg/week) previously treated
-----------------------	---

Reporting group description:

Subjects who were previously treated with GH prior to enrollment in the trial at week 156, received open-labelled somapacitan 0.16mg/kg subcutaneously once weekly until it is available for prescription in subjects' respective countries or until August 2024, at the latest.

Reporting group title	Cohort I Norditropin (0.034mg/somapacitan 0.16mg) week > 364
-----------------------	--

Reporting group description:

Subjects received somapacitan 0.16 mg/kg subcutaneously once weekly until somapacitan was available for prescription for children with GHD in their country or until August 2024, at the latest.

Serious adverse events	Cohort I Norditropin (0.034mg/kg/day) week 0-156	Cohort I Norditropin (0.034mg/somapacitan 0.16mg) week 156-364	Cohort I somapacitan (0.04/0.08/0.16mg/ kg/week) pooled
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 14 (14.29%)	0 / 11 (0.00%)	7 / 45 (15.56%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Surgical and medical procedures			
Adenoidectomy			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Generalised oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic shock			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Vomiting			

subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrotic syndrome			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypopituitarism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Epiphysiolysis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Norovirus infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			

subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort II somapacitan(0.16m g/kg/week) previously treated	Cohort III somapacitan(0.16mg /kg/week) treatment naïve	Cohort III somapacitan(0.16m g/kg/week) previously treated
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Surgical and medical procedures			
Adenoidectomy			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Generalised oedema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic shock			

subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrotic syndrome			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypopituitarism			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Epiphysiolysis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Norovirus infection			

subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchitis			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort I Norditropin (0.034mg/somapacitan 0.16mg) week > 364		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Surgical and medical procedures			
Adenoidectomy			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Generalised oedema			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			

Anaphylactic reaction			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaphylactic shock			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrotic syndrome			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Hypopituitarism			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Epiphysiolysis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			

subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Norovirus infection			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus bronchitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort I Norditropin (0.034mg/kg/day) week 0-156	Cohort I Norditropin (0.034mg/somapacitan 0.16mg) week 156-364	Cohort I somapacitan (0.04/0.08/0.16mg/kg/week) pooled
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 14 (100.00%)	10 / 11 (90.91%)	40 / 45 (88.89%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	4 / 45 (8.89%)
occurrences (all)	0	0	6
Surgical and medical procedures			
Cranial operation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Influenza like illness			

subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	2 / 14 (14.29%)	1 / 11 (9.09%)	18 / 45 (40.00%)
occurrences (all)	5	6	30
Fatigue			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	1 / 45 (2.22%)
occurrences (all)	0	1	1
Malaise			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	1 / 45 (2.22%)
occurrences (all)	0	1	1
Temperature intolerance			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Food allergy			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences (all)	1	0	1
Seasonal allergy			
subjects affected / exposed	1 / 14 (7.14%)	1 / 11 (9.09%)	3 / 45 (6.67%)
occurrences (all)	2	3	5
Social circumstances			
Educational problem			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Social problem			

subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	2 / 45 (4.44%)
occurrences (all)	0	0	3
Cough			
subjects affected / exposed	2 / 14 (14.29%)	1 / 11 (9.09%)	4 / 45 (8.89%)
occurrences (all)	2	1	5
Rhinitis allergic			
subjects affected / exposed	3 / 14 (21.43%)	0 / 11 (0.00%)	6 / 45 (13.33%)
occurrences (all)	3	0	12
Adenoidal hypertrophy			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	3
Oropharyngeal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	4
Rhinorrhoea			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	3
Autism spectrum disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Drug abuse			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Generalised anxiety disorder			

subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 1	0 / 45 (0.00%) 0
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	1 / 45 (2.22%) 1
Blood glucose abnormal subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Blood thyroid stimulating hormone increased subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 1	1 / 45 (2.22%) 1
Platelet count increased subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	4 / 45 (8.89%) 6
Head injury subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3
Arthropod bite subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3
Arthropod sting subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3

Hand fracture subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3
Skin laceration subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3
Cardiac disorders			
Defect conduction intraventricular subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 1	0 / 45 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 1	0 / 45 (0.00%) 0
Nervous system disorders			
Autonomic nervous system imbalance subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Disturbance in attention subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	1 / 11 (9.09%) 1	0 / 45 (0.00%) 0
Febrile convulsion subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	2 / 14 (14.29%) 2	0 / 11 (0.00%) 0	5 / 45 (11.11%) 9
Nystagmus subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Sensory processing disorder subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Speech disorder developmental			

subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Speech disorder			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 14 (14.29%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	2	0	3
Microcytosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Monocytosis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Anisometropia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Optic nerve cupping			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Strabismus			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	2	0	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	4 / 45 (8.89%)
occurrences (all)	0	1	6
Visual impairment			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Swelling of eyelid			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Gastrointestinal disorders			

Constipation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	7 / 45 (15.56%)
occurrences (all)	0	0	13
Diarrhoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	4 / 45 (8.89%)
occurrences (all)	0	0	10
Abdominal pain upper			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	5 / 45 (11.11%)
occurrences (all)	1	0	6
Vomiting			
subjects affected / exposed	1 / 14 (7.14%)	2 / 11 (18.18%)	8 / 45 (17.78%)
occurrences (all)	4	2	9
Nausea			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	4 / 45 (8.89%)
occurrences (all)	0	1	5
Stomatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	4 / 45 (8.89%)
occurrences (all)	0	0	24
Hepatobiliary disorders			
Gallbladder disorder			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Non-alcoholic fatty liver			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	1	0	3
Dermatitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	2 / 45 (4.44%)
occurrences (all)	1	0	2
Eczema asteatotic			

subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Eczema			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	5 / 45 (11.11%)
occurrences (all)	1	0	6
Dermatosis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Dermatitis atopic			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Haemorrhage subcutaneous			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Hair colour changes			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	4
Seborrhoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 11 (9.09%)	6 / 45 (13.33%)
occurrences (all)	1	1	7
Groin pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	1 / 45 (2.22%)
occurrences (all)	0	0	1
Pain in extremity			

subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	4 / 45 (8.89%)
occurrences (all)	1	0	6
Foot deformity			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	0 / 45 (0.00%)
occurrences (all)	0	1	0
Growing pains			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	4
Neck pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	2 / 14 (14.29%)	1 / 11 (9.09%)	8 / 45 (17.78%)
occurrences (all)	2	1	11
Gastroenteritis viral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	4 / 45 (8.89%)
occurrences (all)	0	0	8
Ear infection			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	3 / 14 (21.43%)	2 / 11 (18.18%)	9 / 45 (20.00%)
occurrences (all)	12	4	67
Otitis media			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	7 / 45 (15.56%)
occurrences (all)	1	0	12
Mumps			
subjects affected / exposed	1 / 14 (7.14%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	3 / 14 (21.43%)	1 / 11 (9.09%)	11 / 45 (24.44%)
occurrences (all)	4	1	18
Pneumonia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	0	0	3

Rhinitis			
subjects affected / exposed	3 / 14 (21.43%)	2 / 11 (18.18%)	2 / 45 (4.44%)
occurrences (all)	3	2	3
Respiratory tract infection viral			
subjects affected / exposed	1 / 14 (7.14%)	2 / 11 (18.18%)	1 / 45 (2.22%)
occurrences (all)	3	2	2
Respiratory tract infection			
subjects affected / exposed	2 / 14 (14.29%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	3	0	7
Varicella			
subjects affected / exposed	1 / 14 (7.14%)	1 / 11 (9.09%)	2 / 45 (4.44%)
occurrences (all)	1	1	2
Upper respiratory tract infection			
subjects affected / exposed	2 / 14 (14.29%)	0 / 11 (0.00%)	5 / 45 (11.11%)
occurrences (all)	3	0	10
Tonsillitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	6 / 45 (13.33%)
occurrences (all)	0	0	6
Viral infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	3 / 45 (6.67%)
occurrences (all)	0	2	4
Bronchitis			
subjects affected / exposed	2 / 14 (14.29%)	0 / 11 (0.00%)	3 / 45 (6.67%)
occurrences (all)	3	0	4
COVID-19			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	14 / 45 (31.11%)
occurrences (all)	0	0	17
Conjunctivitis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	2 / 45 (4.44%)
occurrences (all)	0	1	2
Helicobacter infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 45 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 14 (0.00%)	1 / 11 (9.09%)	1 / 45 (2.22%)
occurrences (all)	0	1	1

Hand-foot-and-mouth disease subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Impetigo subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3
Otitis media acute subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	2 / 45 (4.44%) 3
Oral herpes subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Paronychia subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 3
Pharyngitis subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	3 / 45 (6.67%) 7
Scarlet fever subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Pyoderma subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 1	0 / 45 (0.00%) 0
Pharyngitis streptococcal subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	1 / 45 (2.22%) 4
Streptococcal infection subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 2	1 / 45 (2.22%) 1
Tooth abscess subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Metabolism and nutrition disorders Dehydration			

subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Impaired fasting glucose subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 11 (0.00%) 0	0 / 45 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 11 (9.09%) 1	2 / 45 (4.44%) 2

Non-serious adverse events	Cohort II somapacitan(0.16m g/kg/week) previously treated	Cohort III somapacitan(0.16mg /kg/week) treatment naive	Cohort III somapacitan(0.16m g/kg/week) previously treated
Total subjects affected by non-serious adverse events subjects affected / exposed	1 / 1 (100.00%)	2 / 4 (50.00%)	9 / 12 (75.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Surgical and medical procedures Cranial operation subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
General disorders and administration site conditions Influenza like illness subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Pyrexia subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 5	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Fatigue subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	2 / 4 (50.00%) 2	0 / 12 (0.00%) 0
Injection site reaction			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Malaise subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 4 (25.00%) 1	0 / 12 (0.00%) 0
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Food allergy subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Social circumstances Educational problem subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Social problem subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 4 (25.00%) 1	0 / 12 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Adenoidal hypertrophy			

subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 1 (0.00%)	1 / 4 (25.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Autism spectrum disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Drug abuse			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Generalised anxiety disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blood glucose abnormal			

subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Arthropod sting			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hand fracture			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Defect conduction intraventricular			
subjects affected / exposed	0 / 1 (0.00%)	1 / 4 (25.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tachycardia			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Nervous system disorders			
Autonomic nervous system imbalance			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Disturbance in attention			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Febrile convulsion			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Headache			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 4 (25.00%) 1	2 / 12 (16.67%) 3
Nystagmus			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Sensory processing disorder			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Speech disorder developmental			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Speech disorder			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Microcytosis			
subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Monocytosis			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Eye disorders			
Anisometropia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Optic nerve cupping			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Strabismus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Swelling of eyelid			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed	0 / 1 (0.00%)	1 / 4 (25.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 1 (0.00%)	1 / 4 (25.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Gallbladder disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Non-alcoholic fatty liver			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	3
Dermatitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eczema asteatotic			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dermatitis atopic			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Haemorrhage subcutaneous			

subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hair colour changes			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Seborrhoea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Foot deformity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Growing pains			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Infections and infestations			

Gastroenteritis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Ear infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	2
Nasopharyngitis			
subjects affected / exposed	1 / 1 (100.00%)	1 / 4 (25.00%)	3 / 12 (25.00%)
occurrences (all)	12	1	8
Otitis media			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	7	0	0
Mumps			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 1 (100.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Varicella			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 4	0 / 4 (0.00%) 0	3 / 12 (25.00%) 5
Tonsillitis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	1 / 4 (25.00%) 1	3 / 12 (25.00%) 4
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Helicobacter infection subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Hordeolum subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	1 / 12 (8.33%) 1
Hand-foot-and-mouth disease subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Impetigo subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Otitis media acute subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 4 (0.00%) 0	0 / 12 (0.00%) 0

Paronychia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	4
Scarlet fever			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pyoderma			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Streptococcal infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 1 (0.00%)	1 / 4 (25.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Impaired fasting glucose			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 1 (0.00%)	0 / 4 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Non-serious adverse events	Cohort I Norditropin (0.034mg/somapacitan 0.16mg) week > 364		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 5 (40.00%)		

Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Surgical and medical procedures Cranial operation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
General disorders and administration site conditions Influenza like illness subjects affected / exposed occurrences (all) Pain subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all) Injection site reaction subjects affected / exposed occurrences (all) Malaise subjects affected / exposed occurrences (all) Temperature intolerance subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0		
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all) Food allergy	0 / 5 (0.00%) 0		

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Social circumstances Educational problem subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Social problem subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Cough subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Adenoidal hypertrophy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Epistaxis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Psychiatric disorders			

Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Autism spectrum disorder			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Drug abuse			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Generalised anxiety disorder			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Blood glucose abnormal			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Platelet count increased			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Contusion			

subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Head injury			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Arthropod bite			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Arthropod sting			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Hand fracture			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Defect conduction intraventricular			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Ventricular extrasystoles			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Autonomic nervous system imbalance			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Disturbance in attention			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Febrile convulsion			

subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Nystagmus			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Sensory processing disorder			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Speech disorder developmental			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Speech disorder			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Microcytosis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Monocytosis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Eye disorders			
Anisometropia			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Optic nerve cupping			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Strabismus			

subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Conjunctivitis allergic			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Swelling of eyelid			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Gallbladder disorder			

subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Non-alcoholic fatty liver			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Dermatitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Eczema asteatotic			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Dermatosis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Dermatitis atopic			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Haemorrhage subcutaneous			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Hair colour changes			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Seborrhoea			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		

Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Groin pain			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Foot deformity			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Growing pains			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Gastroenteritis viral			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Ear infection			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		

Otitis media			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Mumps			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Respiratory tract infection viral			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Varicella			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 5 (20.00%)		
occurrences (all)	1		
Tonsillitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Viral infection			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		

COVID-19			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Helicobacter infection			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Hordeolum			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Impetigo			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Otitis media acute			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Paronychia			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Scarlet fever			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		
Pyoderma			
subjects affected / exposed	0 / 5 (0.00%)		
occurrences (all)	0		

Pharyngitis streptococcal subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Streptococcal infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Tooth abscess subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Metabolism and nutrition disorders			
Dehydration subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Impaired fasting glucose subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 September 2016	<p>The amendment was implemented to add a 104-week safety extension trial period to the original trial in order to evaluate long-term safety of somapacitan in paediatric patients with GHD.</p> <p>Additional key changes:</p> <ul style="list-style-type: none">- With the addition of Japan as a participating country, it was added that randomisation was stratified by region (Japan and rest-of-the-world) <ol style="list-style-type: none">1)Text on directions for pregnancy in female subjects updated.2)HV was added as a secondary efficacy endpoint.3)Serum somapacitan concentrations and changes during the trial were moved from a secondary safety endpoint to a secondary efficacy endpoint.4)The patient information informed consents (PI-ICs) were updated to be aligned with the changes described above and in Appendix 9.1.1.
05 January 2018	<p>The amendment was prepared to include a description of how subjects that discontinue treatment was to be followed in the trial. After introducing a 2-year safety extension period with amendment no 5 it was necessary to describe which visits and assessments subjects that discontinue trial product should perform.</p>
12 February 2019	<p>The amendment was prepared to introduce a 208-week long-term safety extension trial period in order to evaluate long-term safety of somapacitan in paediatric patients with GHD. The children receiving daily doses of Norditropin FlexPro were to be switched to weekly doses of somapacitan at week 156.</p> <p>Additional key changes:</p> <ol style="list-style-type: none">1) It was added that adult height will be collected on a subset of subjects in the long-term safety extension period.2) Clarification of endpoints for the 26-week main trial period and the 26 week extension trial period.3) Height SDS and HV SDS, insulin-like growth factor-I (IGF-I) SDS and insulin-like growth factor binding protein-3 (IGFBP-3) SDS were added as secondary efficacy endpoints for evaluation after 52 weeks.4) The former secondary supportive safety endpoint, bone age (X-Ray of left hand), was moved to the efficacy section.5) A number of supportive safety endpoints were removed, including evaluation of technical complaints and change from baseline in physical signs, vital signs and laboratory parameters, as they are monitored on an ongoing basis as part of standard pharmacovigilance practice.6) A number of efficacy and safety analyses, not directly linked to the endpoints, were specified.7) The PI-ICs were updated to be aligned with the changes described above.
13 December 2019	<p>The amendment was prepared to introduce two additional age groups; cohort II (less than (<) 2 years and 26 weeks) and cohort III (girls: more than (>) 9 years and less than equal to (\leq) 17 years; boys: >10 years and \leq17 years), of children with GHD to the 208-week long-term safety extension period of the trial. The aim of adding the two age groups, cohorts II and III, was to enrol children with GHD to whom treatment may be relevant based on a request from the US Food and Drug Administration (FDA).</p> <p>Additional key changes in this context:</p> <ol style="list-style-type: none">1) Updated descriptions of the trial design, treatment and rationale for the trial design as well as updated flowcharts to reflect the addition of cohorts II and III.2) Objectives and endpoints were added for cohort II and III3) Inclusion and exclusion criteria were added for cohorts II and III4) Treatment discontinuation criteria were added for cohorts III5) Updates on visit procedures and timing of visits to reflect the addition of cohorts II and III6) Addition of PI-ICs for cohorts II and III including consent for child becoming of legal age.

13 April 2021	The amendment was prepared to clarify that inclusion criterion 21 for cohort III (Bone age (X-ray of left hand and wrist, central reviewed according to Greulich & Pyle atlas) less than chronological age at screening) is only applicable for growth hormone (GH) treatment naïve subjects, as children receiving GH treatment generally have a more advanced bone age than GH treatment naïve children.
31 October 2022	The amendment was prepared to specify that the trial will be concluded for cohort II and III subjects latest August 2024 (expected last end-of-treatment visit for cohort I) and to describe which visits and assessments should be performed when treatment is discontinued.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported